A Phase 3 clinical trial led by Dr. Marwan Fakih at City of Hope has found that combining sotorasib (a KRAS G12C inhibitor) with panitumumab (an EGFR-targeting monoclonal antibody) significantly improves progression-free survival in patients with KRAS G12C-mutated metastatic colorectal cancer that no longer responds to standard chemotherapy. The study, published in the Journal of Clinical Oncology, showed a 30% objective response rate in the high-dose combination group versus just 1.9% in the standard care group. The findings suggest this drug duo may soon become a new standard of care.
Keep Reading
Add A Comment